Lungs Europe

Lungs Europe is a Brussels-based collaboration between the European Lung Foundation (ELF) and the European Respiratory Society (ERS).

Established in November 2019, Lungs Europe allows ELF and ERS to work in partnership and with other important organisations in the respiratory field to drive policy and the regulatory environment in support of lung health at the European level. Lungs Europe is well placed to play a significant role in EU funding programmes and projects related to respiratory health and disease.

ELF is a patient-led organisation that works internationally to bring patients and the public together with healthcare professionals to improve lung health and advance diagnosis, treatment and care.

ERS is the largest scientific and clinical organisation in respiratory medicine in Europe. Its members are scientists, clinicians, allied healthcare professionals and other experts from around the world.

You can find out more information about ELF and ERS activities by going directly to their individual websites:

EU Projects


ELF and ERS collaborate on a number of EU-funded projects that look at unmet medical and societal needs in the respiratory field. The projects address different aspects in the translational process and how observations in the clinic, laboratory or community turns into interventions that improve the health of individuals and the public.

Both ELF (headquarted in Sheffield, UK) and ERS (headquartered in Lausanne, Switzerland) can be partners in HORIZON EUROPE projects. Both organistions are also able to contribute to EU4HEALTH projects through Lungs Europe.

Current projects in which Lungs Europe is involved include:

DRAGON
DRAGON

DRAGON

DRAGON is an Innovative Medicines Initiative (IMI)-funded EU project and is using artificial intelligence (AI) and machine learning to deliver a decision support system for precise coronavirus diagnosis using CT scanning. Learn more on the DRAGON website.


OPTIMA
OPTIMA

OPTIMA

OPTIMA is an Innovative Medicines Initiative (IMI)-funded EU project aiming to ensure that every patient with lung, prostate and breast cancer has access to the most up-to-date individualized treatments and innovative therapies. It is doing this by strengthening shared decision-making using dynamic computer-interpretable guidelines, and using AI-driven technology and tools. Learn more on the OPTIMA website.


UNITE4TB
UNITE4TB

UNITE4TB

UNITE4TB is the newest project of the IMI AMR Accelerator, an Innovative Medicines Initiative (IMI)-funded EU project with the shared goal of progressing the development of new medicines to treat or prevent resistant bacterial infections. The 7-year, project aims to accelerate and improve the clinical evaluation of combinations of existing and novel drugs, with the goal of developing new and highly active TB treatment regimens for drug-resistant and -sensitive TB. Learn more on the UNITE4TB website.


COCOS-IPF

COCOS-IPF

Funded by the European Joint programme for Rare diseases, the “Co-designing a Core Outcome Set for and with patients with Idiopathic Pulmonary Fibrosis” (COCOS-IPF) project aims to develop a Core Outcome Set (COS) and their corresponding measures for IPF care in Europe. The project will involve a transnational collaboration with professionals and patients, a sound methodological underpinning of the work planned, and by paying attention to geographical, socio-economic and healthcare system diversity within Europe, we will succeed to create a set of outcomes that patients and healthcare professionals value the most within IPF care.


INTERACT

INTERACT

Funded by EU4HEALTH, INTERACT aims to improve cancer patient outcomes and the quality of their care across Europe by improving multi-disciplinary care. It will push for a patient-centred medical culture across Europe, creating a new “European Cancer Patient Journey” that is inclusive and effective whilst encouraging cross-border mobility and efforts to cooperate across disciplines and countries.


EUREST-RISE
EUREST-RISE

EUREST-RISE

EUREST-RISE is a project that includes a series of research studies that will make it easier for researchers to examine tobacco products, specifically: the devices used; their purpose; how key design characteristics interact; and assessing groups of people who use them. Lungs Europe will be offering training on communicating research to policymakers/stakeholders, peer scientists, the general public and the media. EU REST RISE is funded by European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement. Learn more on the EUREST-RISE website.


Contact


Lungs Europe

49-51 Rue de Tréves
BE-1040
Brussels
Belgium
T: +32 2 238 53 60
E: info@europeanlung.org

Find us on social media: